Use of sodium nitroprusside in neonates: Efficacy and safety

doi:10.1016/S0022-3476(85)80477-7

The Journal of Pediatrics

Volume 106, Issue 1, January 1985, Pages 102-110

https://doi.org/10.1016/S0022-3476(85)80477-7 Get rights and content

Sodium nitroprusside was administered to 58 neonates, including 11 with severe respiratory distress syndrome, 15 with persistent pulmonary hypertension of the newborn, 28 with clinical shock, three with systemic hypertension, and two with pulmonary hypoplasia, all refractory to conventional intensive therapy. Nitroprusside was infused at 0.2 to 6.0 μg/kg/min for periods of 10 minutes to 126 hours. Infants with severe respiratory distress syndrome had increased Pao₂ and decreased Paco₂ or peak inspiratory pressure, and nearly all (82%) survived. Infants with persistent pulmonary hypertension of the newborn had variable responses; improvement did not correlate with survival, but survival (47%) was identical to that in an earlier series of infants given tolazoline. Infants in shock had improved perfusion, urine output, and serum bicarbonate levels, and these responses were significantly related to survival. Hypertension was controlled in all three hypertensive infants. Adverse effects were very uncommon. Toxic effects were not observed. Sodium nitroprusside is effective and can be used safely in circulatory disorders in the neonate.

References (34)

Gordillo-PaniaguaG et al.
Sodium nitroprusside treatment of severe arterial hypertension in children
J Pediatr
(1975)
AppelbaumA et al.
Afterload reduction and cardiac output in infants early after cardiac surgery
Am J Cardiol
(1977)
DillonTR et al.
Vasodilator therapy for congestive heart failure
J Pediatr
(1980)
FoxWW et al.
Persistent pulmonary hypertension in the neonate: Diagnosis and management
J Pediatr
(1983)
GoetzmanBW et al.
Neonatal hypoxia and pulmonary vasospasm: Response to tolazoline
J Pediatr
(1976)
StevensonDK et al.
Refractory hypoxemia associated with neonatal pulmonary disease: The use and limitations of tolazoline
J Pediatr
(1979)
WeigeltJA et al.
Pharmacologic alterations in pulmonary artery pressure in the adult respiratory distress syndrome
J Surg Res
(1982)
VeseyCJ et al.
Cyanide and thiocyanate concentrations following sodium nitroprusside infusion in man
Br J Anaesth
(1976)
GilboaN et al.
Severe hypertension in newborn after pyeloplasty of hydronephrotic kidney
Urology
(1983)
CohenRS et al.
Late morbidity among survivors of respiratory therapy treated with tolazoline
J Pediatr
(1980)

PalmerRF et al.

Sodium nitroprusside

N Engl J Med

(1975)

TinkerJH et al.

Sodium nitroprusside: Pharmacology, toxicology and therapeutics

Anesthesiology

(1976)

DaviesDW et al.

Sodium nitroprusside in children: Observations on metabolism during normal and abnormal responses

Can Anaesth Soc J

(1975)

BeekmanRH et al.

Vasodilator therapy in children: Acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation

Pediatrics

(1984)

AbbottTR et al.

Sodium nitroprusside in idiopathic respiratory distress syndrome

Br Med J

(1978)

BeverleyDW et al.

Early use of sodium nitroprusside in respiratory distress syndrome

Arch Dis Child

(1979)

BrownBW et al.

Statistics: A biomedical introduction

Cited by (69)

Neonatal Hypertension
2022, Clinics in Perinatology
Citation Excerpt :
Given risk for side effects in general it is helpful to avoid using ACE inhibitors until after infants have reached a corrected postmenstrual age of 44 weeks.2,74,75 In neonates with acute severe hypertension, continuous intravenous infusions, such as nicardipine, sodium nitroprusside, esmolol, and labetalol, have the important benefit of being easily titratable to keep the blood pressure within the desired range.39,75–82 When used, blood pressure should be monitored continuously using an indwelling intra-arterial catheter or if necessary, an automated oscillometric device taking regular repeat blood pressure measurements.
The hypertensive neonate
2020, Seminars in Fetal and Neonatal Medicine
Citation Excerpt :
Several case series suggest that the intravenous calcium channel blocker nicardipine may be particularly useful in infants with acute severe hypertension [77,78]. Other intravenous antihypertensives that have been reported effective in neonates include sodium nitroprusside, esmolol, and labetalol [79–81]. Whenever intravenous infusions are used, the neonate's BP should be monitored continuously, preferably via an indwelling arterial catheter, alternatively using an automated device to obtain repeated cuff readings, so that the infusion can be titrated to the desired BP reduction.
Hypertension in neonates is increasingly recognized because of improvements in neonatal intensive care that have led to improved survival of premature infants. Although normative data on neonatal blood pressure remain limited, several factors appear to be important in determining blood pressure levels in neonates, especially gestational age, birth weight and maternal factors. Incidence is around 1% in most studies and identification depends on careful blood pressure measurement. Common causes of neonatal hypertension include umbilical catheter associated thrombosis, renal parenchymal disease, and chronic lung disease, and can usually be identified with careful diagnostic evaluation. Given limited data on long-term outcomes and use of antihypertensive medications in these infants, clinical expertise may need to be relied upon to decide the best approach to treatment. This review will discuss these concepts and identify evidence gaps that should be addressed.
Neonatal Hypertension: Diagnosis and Management
2018, Nephrology and Fluid/Electrolyte Physiology: Neonatology Questions and Controversies
Hypertension in neonates is increasingly recognized as a result of advances in our ability to identify, evaluate, and care for premature infants. Normative data on normal blood pressure (BP) in term and preterm infants remain limited, although a variety of factors are clearly important, including birth weight, gestational age, and postmenstrual age. A focused evaluation will usually lead to identification of the cause of hypertension in an affected neonate; thromboembolism, kidney diseases, and chronic lung disease will account for most cases. Individual clinical judgment must be relied upon to decide on the most appropriate approach to treatment, with some infants needing either intravenous or oral antihypertensive medications. Outcome is usually good, although few long-term data are available. Areas for further research include development of large-scale normative data, generation of evidence-based treatment recommendations, and better information on long-term outcome.
Pharmacology of cardiovascular drugs
2018, Critical Heart Disease in Infants and Children
The triad of preload, afterload, and inotropic state of the heart determines stroke volume, which together with heart rate determines cardiac output. The parasympathetic and sympathetic nervous systems regulate cardiac inotropy (contractility), chronotropy (heart rate), and lusitropy (myocardial relaxation). An understanding of the anatomy, physiology, and molecular biology of the sympathetic and parasympathetic nervous systems forms the basis of pharmacologic manipulation of the cardiovascular system. This chapter presents basic principles and clinical applications of medicinal therapies used to optimize cardiac output and systemic perfusion.
Use of Vasodilators in Heart Failure
2018, Heart Failure in the Child and Young Adult: From Bench to Bedside
Oral vasodilator therapy remains the cornerstone of treatment for heart failure in the young, but the evidence base is limited. The vast majority of clinical trials (as well as many physiological and pathological studies) in heart failure have taken place in adult populations; the pediatric cardiologist is therefore forced to base much of their knowledge on extrapolation on these. It is important, however, to bear in mind the axiom “children are not small adults,” and many oral vasodilator drugs of proven benefit in adults have shown unconvincing use in children (Kantor et al., 2010; Hsu et al., 2010; Shaddy et al., 2007; Dore et al., 2005; Hechter et al., 2001; van der Bom et al., 2013). The reasons for these discrepancies remain opaque (Rossano et al., 2014), but certainly some studies have been underpowered (Shaddy et al., 2007). What is certain is that the dearth of large-scale, multicenter, high-quality trials in pediatric cardiology is a frustration commonly found in major guidelines on the subject (Kirk et al., 2014; Kantor et al., 2013).
Use of Vasodilators in Heart Failure
2017, Heart Failure in the Child and Young Adult: From Bench to Bedside
Oral vasodilator therapy remains the cornerstone of treatment for heart failure in the young, but the evidence base is limited. The vast majority of clinical trials (as well as many physiological and pathological studies) in heart failure have taken place in adult populations; the pediatric cardiologist is therefore forced to base much of their knowledge on extrapolation on these. It is important, however, to bear in mind the axiom “children are not small adults,” and many oral vasodilator drugs of proven benefit in adults have shown unconvincing use in children (Kantor et al., 2010; Hsu et al., 2010; Shaddy et al., 2007; Dore et al., 2005; Hechter et al., 2001; van der Bom et al., 2013). The reasons for these discrepancies remain opaque (Rossano et al., 2014), but certainly some studies have been underpowered (Shaddy et al., 2007). What is certain is that the dearth of large-scale, multicenter, high-quality trials in pediatric cardiology is a frustration commonly found in major guidelines on the subject (Kirk et al., 2014; Kantor et al., 2013).

View all citing articles on Scopus

^†: Supported by Grant RR-81 from the General Clinical Research Centers Program, Division of Research Resources, National Institutes of Health, and by the Christopher Taylor Harrison Fund.

View full text

Use of sodium nitroprusside in neonates: Efficacy and safety†

J Pediatr

Am J Cardiol

J Pediatr

J Pediatr

J Pediatr

J Pediatr

J Surg Res

Br J Anaesth

Urology

J Pediatr

Sodium nitroprusside

N Engl J Med

Sodium nitroprusside: Pharmacology, toxicology and therapeutics

Anesthesiology

Sodium nitroprusside in children: Observations on metabolism during normal and abnormal responses

Can Anaesth Soc J

Vasodilator therapy in children: Acute and chronic effects in children with left ventricular dysfunction or mitral regurgitation

Pediatrics

Sodium nitroprusside in idiopathic respiratory distress syndrome

Br Med J

Early use of sodium nitroprusside in respiratory distress syndrome

Arch Dis Child

Statistics: A biomedical introduction